Spero Therapeutics Inc

SPRO

NASDAQ. Currency in USD

1.61 -0.07 ( -4.17% )

Real time prices: December 19

Market Cap.
83.36M
Beta (5Y monthly)
0.76
Price/Earnings
-
EPS (TTM)
-3.11
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
745,182
1y Target Est.
6.33
Day's Range
1.60
-
1.70
52 Week's Range
0.68
-
10.90

Historical Summary

Performance
EPS growth
Share Buybacks

About Spero Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://sperotherapeutics.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
32.32M
Employees
41
Address
675 Massachusetts Avenue, Cambridge, MA, United States, 02139
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Latest news

Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a...
By GlobeNewswire Inc. - 10 weeks ago

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates
Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for...
By Zacks Investment Research - 11 weeks ago

Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update
Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update

Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which...
By GlobeNewswire Inc. - 11 weeks ago

Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of 7.38% and 20.69%, respectively, for the...
By Zacks Investment Research - 12 weeks ago

Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates
Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates

Trevena (TRVN) delivered earnings and revenue surprises of 0% and 203.06%, respectively, for the quarter...
By Zacks Investment Research - 12 weeks ago

Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 12.16% and 34.43%, respectively, for...
By Zacks Investment Research - 12 weeks ago

Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a...
By GlobeNewswire Inc. - 12 weeks ago

Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset...
By GlobeNewswire Inc. - 12 weeks ago